Prospective CYP2C19-Guided Voriconazole Prophylaxis in Neutropenic AML Patients Reduces the Incidence of Subtherapeutic Antifungal Plasma Concentrations

A risk mitigation strategy was implemented to determine if a higher prophylactic voriconazole dosage in CYP2C19 rapid metabolizer neutropenic AML patients reduces the incidence of subtherapeutic trough concentrations. AML patients (n=263) were preemptively genotyped for CYP2C19*2, *3, and *17 allele...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Pharmacol Ther
Autors principals: Hicks, J. Kevin, Quilitz, Rod E., Komrokji, Rami S., Kubal, Timothy E., Lancet, Jeffrey E., Pasikhova, Yanina, Qin, Dahui, So, Wonhee, Caceres, Gisela, Kelly, Kerry, Salchert, Yasmina S., Shahbazian, Kevin, Abbas-Aghababazadeh, Farnoosh, Fridley, Brooke L., Velez, Ana P., McLeod, Howard L., Greene, John N.
Format: Artigo
Idioma:Inglês
Publicat: 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7018540/
https://ncbi.nlm.nih.gov/pubmed/31549389
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.1641
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars